Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Inclusion Criteria

• •Histologically proven, unresectable advanced or metastatic cholangiocarcinoma patients.
• •the world health organization (WHO)/ECOG physical state (PS) to 0 or 1.
• •at least 1 RECIST 1.1 standard target lesions.
• •not previously received immunotherapy, including but not limited to CTLA 4, PD-L1 or/and PD-1 inhibitors.
• •adequate organ and bone marrow function, defined as follows: 9.0 g/dL or higher hemoglobin; neutrophil count 1.5 x 109 / L; platelet count 100 x 109 / L.